Rani Therapeutics: New RT-111 Development Program, Corporate Update

  Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis -

- RT-102 Phase 1 repeat-dose topline data anticipated in 4Q 2022 -

- Initiation of in vivo studies with fully-autonomous RaniPill HC anticipated in 4Q 2022 -

https://www.biospace.com/article/releases/rani-therapeutics-announces-new-rt-111-development-program-and-provides-corporate-update/